Real world drug survival of guselkumab, ixekizumab and secukinumab for psoriasis.

Guselkumab is an IL-23 inhibitor approved for moderate-to-severe plaque psoriasis that has demonstrated safety and efficacy in phase III clinical trials1-3 . However, there is scarce data regarding its drug survival in clinical practice.